UCB (Euronext Brussels: UCB), a global biopharmaceutical company, today announced that KYGEVVI® has been granted approval by the U.S. Food and Drug Administration (FDA) for the treatment of adults and ...
The First And Only Treatment For Adults And Children Living With Thymidine Kinase 2 Deficiency (Tk2d). <li /> Approved indication: KYGEVVITM (doxecitine and doxribtimine) powder for oral solution (2 ...
Barchart on MSN
Should You Buy the Dip in Intellia Therapeutics Stock?
In biotech, success often begins in the lab — and for CRISPR pioneers, every clinical trial feels like a moonshot.
Background Pulsed field ablation (PFA) has emerged as a promising non-thermal alternative to conventional atrial fibrillation ...
KYGEVVI™ (doxecitine and doxribtimine) powder for oral solution (2g/2g) is approved for the treatment of thymidine kinase 2 ...
Findings seen for lipoprotein a, remnant cholesterol, and high-sensitivity C-reactive protein.
A patient dosed with Intellia Therapeutics’ CRISPR gene therapy has died after suffering a severe liver-associated adverse ...
A common chemical used in dry cleaning and for certain consumer products called tetrachloroethylene (PCE) may triple a person's risk for liver fibrosis, a new study reports.
A Concordia-led research team has created one of the first reference charts showing how children's adipose (fat) and muscle levels change with age and sex—a breakthrough that could help identify young ...
Q3 2025 net product revenues grew to $14.3 million; Q3 2025 total net product revenues were $56.8 million Operational pilot ...
The FDA has approved Kygevvi (doxecitine and doxribtimine) for the treatment of TK2d in adults and pediatric patients with an age of symptom onset on or before 12 years.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback